In patients with disseminated non-tuberculous mycobacterial infections driven by anti-IFN-γ autoantibodies, B cell-depleting therapy with rituximab has demonstrated efficacy in lowering autoantibody titers and enhancing infection control [24]. The gene discussed is IFNG; the disease is infection.